Cargando…

Sarcopenia: investigation of metabolic changes and its associated mechanisms

BACKGROUND: Sarcopenia is one of the most predominant musculoskeletal diseases of the elderly, defined as age-related progressive and generalized loss of muscle mass with a simultaneous reduction in muscle strength and/or function. Using metabolomics, we aimed to examine the association between sarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques, Jair, Shokry, Engy, Uhl, Olaf, Baber, Lisa, Hofmeister, Fabian, Jarmusch, Stefanie, Bidlingmaier, Martin, Ferrari, Uta, Koletzko, Berthold, Drey, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850598/
https://www.ncbi.nlm.nih.gov/pubmed/36658632
http://dx.doi.org/10.1186/s13395-022-00312-w
_version_ 1784872221275062272
author Marques, Jair
Shokry, Engy
Uhl, Olaf
Baber, Lisa
Hofmeister, Fabian
Jarmusch, Stefanie
Bidlingmaier, Martin
Ferrari, Uta
Koletzko, Berthold
Drey, Michael
author_facet Marques, Jair
Shokry, Engy
Uhl, Olaf
Baber, Lisa
Hofmeister, Fabian
Jarmusch, Stefanie
Bidlingmaier, Martin
Ferrari, Uta
Koletzko, Berthold
Drey, Michael
author_sort Marques, Jair
collection PubMed
description BACKGROUND: Sarcopenia is one of the most predominant musculoskeletal diseases of the elderly, defined as age-related progressive and generalized loss of muscle mass with a simultaneous reduction in muscle strength and/or function. Using metabolomics, we aimed to examine the association between sarcopenia and the plasma metabolic profile of sarcopenic patients, measured using a targeted HPLC-MS/MS platform. METHODS: Plasma samples from 22 (17 men) hip fracture patients undergoing surgery (8 sarcopenic, age 81.4+6.3, and 14 non-sarcopenic, age 78.4±8.1) were analyzed. T test, fold change, orthogonal partial least squares discriminant analysis, and sparse partial least squares discriminant analysis were used for mining significant features. Metabolite set enrichment analysis and mediation analysis by PLSSEM were thereafter performed. RESULTS: Using a univariate analysis for sarcopenia z score, the amino acid citrulline was the only metabolite with a significant group difference after FDR correction. Positive trends were observed between the sarcopenia z score and very long-chain fatty acids as well as dicarboxylic acid carnitines. Multivariate analysis showed citrulline, non-esterified fatty acid 26:2, and decanedioyl carnitine as the top three metabolites according to the variable importance in projection using oPLS-DA and loadings weight by sPLS-DA. Metabolite set enrichment analysis showed carnitine palmitoyltransferase deficiency (II) as the highest condition related to the metabolome. CONCLUSIONS: We observed a difference in the plasma metabolic profile in association with different measures of sarcopenia, which identifies very long-chain fatty acids, Carn.DC and citrulline as key variables associated with the disease severity. These findings point to a potential link between sarcopenia and mitochondrial dysfunction and portraits a number of possible biochemical pathways which might be involved in the disease pathogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13395-022-00312-w.
format Online
Article
Text
id pubmed-9850598
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98505982023-01-20 Sarcopenia: investigation of metabolic changes and its associated mechanisms Marques, Jair Shokry, Engy Uhl, Olaf Baber, Lisa Hofmeister, Fabian Jarmusch, Stefanie Bidlingmaier, Martin Ferrari, Uta Koletzko, Berthold Drey, Michael Skelet Muscle Research BACKGROUND: Sarcopenia is one of the most predominant musculoskeletal diseases of the elderly, defined as age-related progressive and generalized loss of muscle mass with a simultaneous reduction in muscle strength and/or function. Using metabolomics, we aimed to examine the association between sarcopenia and the plasma metabolic profile of sarcopenic patients, measured using a targeted HPLC-MS/MS platform. METHODS: Plasma samples from 22 (17 men) hip fracture patients undergoing surgery (8 sarcopenic, age 81.4+6.3, and 14 non-sarcopenic, age 78.4±8.1) were analyzed. T test, fold change, orthogonal partial least squares discriminant analysis, and sparse partial least squares discriminant analysis were used for mining significant features. Metabolite set enrichment analysis and mediation analysis by PLSSEM were thereafter performed. RESULTS: Using a univariate analysis for sarcopenia z score, the amino acid citrulline was the only metabolite with a significant group difference after FDR correction. Positive trends were observed between the sarcopenia z score and very long-chain fatty acids as well as dicarboxylic acid carnitines. Multivariate analysis showed citrulline, non-esterified fatty acid 26:2, and decanedioyl carnitine as the top three metabolites according to the variable importance in projection using oPLS-DA and loadings weight by sPLS-DA. Metabolite set enrichment analysis showed carnitine palmitoyltransferase deficiency (II) as the highest condition related to the metabolome. CONCLUSIONS: We observed a difference in the plasma metabolic profile in association with different measures of sarcopenia, which identifies very long-chain fatty acids, Carn.DC and citrulline as key variables associated with the disease severity. These findings point to a potential link between sarcopenia and mitochondrial dysfunction and portraits a number of possible biochemical pathways which might be involved in the disease pathogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13395-022-00312-w. BioMed Central 2023-01-19 /pmc/articles/PMC9850598/ /pubmed/36658632 http://dx.doi.org/10.1186/s13395-022-00312-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Marques, Jair
Shokry, Engy
Uhl, Olaf
Baber, Lisa
Hofmeister, Fabian
Jarmusch, Stefanie
Bidlingmaier, Martin
Ferrari, Uta
Koletzko, Berthold
Drey, Michael
Sarcopenia: investigation of metabolic changes and its associated mechanisms
title Sarcopenia: investigation of metabolic changes and its associated mechanisms
title_full Sarcopenia: investigation of metabolic changes and its associated mechanisms
title_fullStr Sarcopenia: investigation of metabolic changes and its associated mechanisms
title_full_unstemmed Sarcopenia: investigation of metabolic changes and its associated mechanisms
title_short Sarcopenia: investigation of metabolic changes and its associated mechanisms
title_sort sarcopenia: investigation of metabolic changes and its associated mechanisms
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850598/
https://www.ncbi.nlm.nih.gov/pubmed/36658632
http://dx.doi.org/10.1186/s13395-022-00312-w
work_keys_str_mv AT marquesjair sarcopeniainvestigationofmetabolicchangesanditsassociatedmechanisms
AT shokryengy sarcopeniainvestigationofmetabolicchangesanditsassociatedmechanisms
AT uhlolaf sarcopeniainvestigationofmetabolicchangesanditsassociatedmechanisms
AT baberlisa sarcopeniainvestigationofmetabolicchangesanditsassociatedmechanisms
AT hofmeisterfabian sarcopeniainvestigationofmetabolicchangesanditsassociatedmechanisms
AT jarmuschstefanie sarcopeniainvestigationofmetabolicchangesanditsassociatedmechanisms
AT bidlingmaiermartin sarcopeniainvestigationofmetabolicchangesanditsassociatedmechanisms
AT ferrariuta sarcopeniainvestigationofmetabolicchangesanditsassociatedmechanisms
AT koletzkoberthold sarcopeniainvestigationofmetabolicchangesanditsassociatedmechanisms
AT dreymichael sarcopeniainvestigationofmetabolicchangesanditsassociatedmechanisms